Eintrag weiter verarbeiten
Effects of Rituximab on JAK-STAT and NF-κB signaling pathways in acute lymphoblastic leukemia and chronic lymphocytic leukemia
Gespeichert in:
| Zeitschriftentitel: | Turkish Journal of Biochemistry |
|---|---|
| Personen und Körperschaften: | , , , , , |
| In: | Turkish Journal of Biochemistry, 44, 2019, 4, S. 499-509 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Walter de Gruyter GmbH
|
| Schlagwörter: |
| author_facet |
Dalmızrak, Ayşegül Günel, Nur Selvi Tezcanlı Kaymaz, Burçin Şahin, Fahri Saydam, Güray Kosova, Buket Dalmızrak, Ayşegül Günel, Nur Selvi Tezcanlı Kaymaz, Burçin Şahin, Fahri Saydam, Güray Kosova, Buket |
|---|---|
| author |
Dalmızrak, Ayşegül Günel, Nur Selvi Tezcanlı Kaymaz, Burçin Şahin, Fahri Saydam, Güray Kosova, Buket |
| spellingShingle |
Dalmızrak, Ayşegül Günel, Nur Selvi Tezcanlı Kaymaz, Burçin Şahin, Fahri Saydam, Güray Kosova, Buket Turkish Journal of Biochemistry Effects of Rituximab on JAK-STAT and NF-κB signaling pathways in acute lymphoblastic leukemia and chronic lymphocytic leukemia Biochemistry (medical) Clinical Biochemistry Molecular Biology Biochemistry |
| author_sort |
dalmızrak, ayşegül |
| spelling |
Dalmızrak, Ayşegül Günel, Nur Selvi Tezcanlı Kaymaz, Burçin Şahin, Fahri Saydam, Güray Kosova, Buket 1303-829X 0250-4685 Walter de Gruyter GmbH Biochemistry (medical) Clinical Biochemistry Molecular Biology Biochemistry http://dx.doi.org/10.1515/tjb-2018-0321 <jats:title>Abstract</jats:title> <jats:sec id="j_tjb-2018-0321_s_999_w2aab3b7c29b1b6b1aab1c15b1Aa"> <jats:title>Objectives</jats:title> <jats:p>Rituximab is a monoclonal antibody that targets the B-lymphocyte surface antigen CD20. It is used in the treatment of some diseases including B-cell chronic lymphocytic leukemia (B-CLL). There are a lot of data regarding effect of Rituximab on lymphoma cells. But, there is no satisfactory information about the effect of Rituximab on the signaling pathways in leukemia cells. In this study, it was aimed to understand the effect of Rituximab on JAK-STAT and NF-κB signaling pathways in B-cell acute lymphoblastic leukemia (B-ALL) and B-CLL.</jats:p> </jats:sec> <jats:sec id="j_tjb-2018-0321_s_998_w2aab3b7c29b1b6b1aab1c15b2Aa"> <jats:title>Material and methods</jats:title> <jats:p>Apoptotic effect of Rituximab in the TANOUE (B-ALL) and EHEB (B-CLL) cell lines were evaluated by using the Annexin V method. mRNA expression levels of STAT3 and RelA were analysed by quantitative RT-PCR (Q-PCR). Alterations in STAT3 and RelA protein expressions were detected by using a chromogenic alkaline phosphatase assay after Western Blotting.</jats:p> </jats:sec> <jats:sec id="j_tjb-2018-0321_s_997_w2aab3b7c29b1b6b1aab1c15b3Aa"> <jats:title>Results</jats:title> <jats:p>Rituximab had no apoptotic effect on both cell lines. Complement-mediated cytotoxicity was only detected in EHEB cells. mRNA and protein expressions of STAT3 and RelA genes were decreased following Rituximab treatment.</jats:p> </jats:sec> <jats:sec id="j_tjb-2018-0321_s_996_w2aab3b7c29b1b6b1aab1c15b4Aa"> <jats:title>Conclusion</jats:title> <jats:p>Our preliminary results suggest that the use of Rituximab might be effective in B-ALL though both signaling pathways.</jats:p> </jats:sec> Effects of Rituximab on JAK-STAT and NF-κB signaling pathways in acute lymphoblastic leukemia and chronic lymphocytic leukemia Turkish Journal of Biochemistry |
| doi_str_mv |
10.1515/tjb-2018-0321 |
| facet_avail |
Online |
| finc_class_facet |
Medizin Biologie Chemie und Pharmazie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTUxNS90amItMjAxOC0wMzIx |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTUxNS90amItMjAxOC0wMzIx |
| institution |
DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-D161 DE-Zi4 DE-Gla1 DE-15 DE-Pl11 DE-Rs1 DE-14 DE-105 |
| imprint |
Walter de Gruyter GmbH, 2019 |
| imprint_str_mv |
Walter de Gruyter GmbH, 2019 |
| issn |
1303-829X 0250-4685 |
| issn_str_mv |
1303-829X 0250-4685 |
| language |
English |
| mega_collection |
Walter de Gruyter GmbH (CrossRef) |
| match_str |
dalmizrak2019effectsofrituximabonjakstatandnfkbsignalingpathwaysinacutelymphoblasticleukemiaandchroniclymphocyticleukemia |
| publishDateSort |
2019 |
| publisher |
Walter de Gruyter GmbH |
| recordtype |
ai |
| record_format |
ai |
| series |
Turkish Journal of Biochemistry |
| source_id |
49 |
| title |
Effects of Rituximab on JAK-STAT and NF-κB signaling pathways in acute lymphoblastic leukemia and chronic lymphocytic leukemia |
| title_unstemmed |
Effects of Rituximab on JAK-STAT and NF-κB signaling pathways in acute lymphoblastic leukemia and chronic lymphocytic leukemia |
| title_full |
Effects of Rituximab on JAK-STAT and NF-κB signaling pathways in acute lymphoblastic leukemia and chronic lymphocytic leukemia |
| title_fullStr |
Effects of Rituximab on JAK-STAT and NF-κB signaling pathways in acute lymphoblastic leukemia and chronic lymphocytic leukemia |
| title_full_unstemmed |
Effects of Rituximab on JAK-STAT and NF-κB signaling pathways in acute lymphoblastic leukemia and chronic lymphocytic leukemia |
| title_short |
Effects of Rituximab on JAK-STAT and NF-κB signaling pathways in acute lymphoblastic leukemia and chronic lymphocytic leukemia |
| title_sort |
effects of rituximab on jak-stat and nf-κb signaling pathways in acute lymphoblastic leukemia and chronic lymphocytic leukemia |
| topic |
Biochemistry (medical) Clinical Biochemistry Molecular Biology Biochemistry |
| url |
http://dx.doi.org/10.1515/tjb-2018-0321 |
| publishDate |
2019 |
| physical |
499-509 |
| description |
<jats:title>Abstract</jats:title>
<jats:sec id="j_tjb-2018-0321_s_999_w2aab3b7c29b1b6b1aab1c15b1Aa">
<jats:title>Objectives</jats:title>
<jats:p>Rituximab is a monoclonal antibody that targets the B-lymphocyte surface antigen CD20. It is used in the treatment of some diseases including B-cell chronic lymphocytic leukemia (B-CLL). There are a lot of data regarding effect of Rituximab on lymphoma cells. But, there is no satisfactory information about the effect of Rituximab on the signaling pathways in leukemia cells. In this study, it was aimed to understand the effect of Rituximab on JAK-STAT and NF-κB signaling pathways in B-cell acute lymphoblastic leukemia (B-ALL) and B-CLL.</jats:p>
</jats:sec>
<jats:sec id="j_tjb-2018-0321_s_998_w2aab3b7c29b1b6b1aab1c15b2Aa">
<jats:title>Material and methods</jats:title>
<jats:p>Apoptotic effect of Rituximab in the TANOUE (B-ALL) and EHEB (B-CLL) cell lines were evaluated by using the Annexin V method. mRNA expression levels of STAT3 and RelA were analysed by quantitative RT-PCR (Q-PCR). Alterations in STAT3 and RelA protein expressions were detected by using a chromogenic alkaline phosphatase assay after Western Blotting.</jats:p>
</jats:sec>
<jats:sec id="j_tjb-2018-0321_s_997_w2aab3b7c29b1b6b1aab1c15b3Aa">
<jats:title>Results</jats:title>
<jats:p>Rituximab had no apoptotic effect on both cell lines. Complement-mediated cytotoxicity was only detected in EHEB cells. mRNA and protein expressions of STAT3 and RelA genes were decreased following Rituximab treatment.</jats:p>
</jats:sec>
<jats:sec id="j_tjb-2018-0321_s_996_w2aab3b7c29b1b6b1aab1c15b4Aa">
<jats:title>Conclusion</jats:title>
<jats:p>Our preliminary results suggest that the use of Rituximab might be effective in B-ALL though both signaling pathways.</jats:p>
</jats:sec> |
| container_issue |
4 |
| container_start_page |
499 |
| container_title |
Turkish Journal of Biochemistry |
| container_volume |
44 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792337176431689729 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T15:12:10.844Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Effects+of+Rituximab+on+JAK-STAT+and+NF-%CE%BAB+signaling+pathways+in+acute+lymphoblastic+leukemia+and+chronic+lymphocytic+leukemia&rft.date=2019-08-27&genre=article&issn=0250-4685&volume=44&issue=4&spage=499&epage=509&pages=499-509&jtitle=Turkish+Journal+of+Biochemistry&atitle=Effects+of+Rituximab+on+JAK-STAT+and+NF-%CE%BAB+signaling+pathways+in+acute+lymphoblastic+leukemia+and+chronic+lymphocytic+leukemia&aulast=Kosova&aufirst=Buket&rft_id=info%3Adoi%2F10.1515%2Ftjb-2018-0321&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792337176431689729 |
| author | Dalmızrak, Ayşegül, Günel, Nur Selvi, Tezcanlı Kaymaz, Burçin, Şahin, Fahri, Saydam, Güray, Kosova, Buket |
| author_facet | Dalmızrak, Ayşegül, Günel, Nur Selvi, Tezcanlı Kaymaz, Burçin, Şahin, Fahri, Saydam, Güray, Kosova, Buket, Dalmızrak, Ayşegül, Günel, Nur Selvi, Tezcanlı Kaymaz, Burçin, Şahin, Fahri, Saydam, Güray, Kosova, Buket |
| author_sort | dalmızrak, ayşegül |
| container_issue | 4 |
| container_start_page | 499 |
| container_title | Turkish Journal of Biochemistry |
| container_volume | 44 |
| description | <jats:title>Abstract</jats:title> <jats:sec id="j_tjb-2018-0321_s_999_w2aab3b7c29b1b6b1aab1c15b1Aa"> <jats:title>Objectives</jats:title> <jats:p>Rituximab is a monoclonal antibody that targets the B-lymphocyte surface antigen CD20. It is used in the treatment of some diseases including B-cell chronic lymphocytic leukemia (B-CLL). There are a lot of data regarding effect of Rituximab on lymphoma cells. But, there is no satisfactory information about the effect of Rituximab on the signaling pathways in leukemia cells. In this study, it was aimed to understand the effect of Rituximab on JAK-STAT and NF-κB signaling pathways in B-cell acute lymphoblastic leukemia (B-ALL) and B-CLL.</jats:p> </jats:sec> <jats:sec id="j_tjb-2018-0321_s_998_w2aab3b7c29b1b6b1aab1c15b2Aa"> <jats:title>Material and methods</jats:title> <jats:p>Apoptotic effect of Rituximab in the TANOUE (B-ALL) and EHEB (B-CLL) cell lines were evaluated by using the Annexin V method. mRNA expression levels of STAT3 and RelA were analysed by quantitative RT-PCR (Q-PCR). Alterations in STAT3 and RelA protein expressions were detected by using a chromogenic alkaline phosphatase assay after Western Blotting.</jats:p> </jats:sec> <jats:sec id="j_tjb-2018-0321_s_997_w2aab3b7c29b1b6b1aab1c15b3Aa"> <jats:title>Results</jats:title> <jats:p>Rituximab had no apoptotic effect on both cell lines. Complement-mediated cytotoxicity was only detected in EHEB cells. mRNA and protein expressions of STAT3 and RelA genes were decreased following Rituximab treatment.</jats:p> </jats:sec> <jats:sec id="j_tjb-2018-0321_s_996_w2aab3b7c29b1b6b1aab1c15b4Aa"> <jats:title>Conclusion</jats:title> <jats:p>Our preliminary results suggest that the use of Rituximab might be effective in B-ALL though both signaling pathways.</jats:p> </jats:sec> |
| doi_str_mv | 10.1515/tjb-2018-0321 |
| facet_avail | Online |
| finc_class_facet | Medizin, Biologie, Chemie und Pharmazie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTUxNS90amItMjAxOC0wMzIx |
| imprint | Walter de Gruyter GmbH, 2019 |
| imprint_str_mv | Walter de Gruyter GmbH, 2019 |
| institution | DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-D161, DE-Zi4, DE-Gla1, DE-15, DE-Pl11, DE-Rs1, DE-14, DE-105 |
| issn | 1303-829X, 0250-4685 |
| issn_str_mv | 1303-829X, 0250-4685 |
| language | English |
| last_indexed | 2024-03-01T15:12:10.844Z |
| match_str | dalmizrak2019effectsofrituximabonjakstatandnfkbsignalingpathwaysinacutelymphoblasticleukemiaandchroniclymphocyticleukemia |
| mega_collection | Walter de Gruyter GmbH (CrossRef) |
| physical | 499-509 |
| publishDate | 2019 |
| publishDateSort | 2019 |
| publisher | Walter de Gruyter GmbH |
| record_format | ai |
| recordtype | ai |
| series | Turkish Journal of Biochemistry |
| source_id | 49 |
| spelling | Dalmızrak, Ayşegül Günel, Nur Selvi Tezcanlı Kaymaz, Burçin Şahin, Fahri Saydam, Güray Kosova, Buket 1303-829X 0250-4685 Walter de Gruyter GmbH Biochemistry (medical) Clinical Biochemistry Molecular Biology Biochemistry http://dx.doi.org/10.1515/tjb-2018-0321 <jats:title>Abstract</jats:title> <jats:sec id="j_tjb-2018-0321_s_999_w2aab3b7c29b1b6b1aab1c15b1Aa"> <jats:title>Objectives</jats:title> <jats:p>Rituximab is a monoclonal antibody that targets the B-lymphocyte surface antigen CD20. It is used in the treatment of some diseases including B-cell chronic lymphocytic leukemia (B-CLL). There are a lot of data regarding effect of Rituximab on lymphoma cells. But, there is no satisfactory information about the effect of Rituximab on the signaling pathways in leukemia cells. In this study, it was aimed to understand the effect of Rituximab on JAK-STAT and NF-κB signaling pathways in B-cell acute lymphoblastic leukemia (B-ALL) and B-CLL.</jats:p> </jats:sec> <jats:sec id="j_tjb-2018-0321_s_998_w2aab3b7c29b1b6b1aab1c15b2Aa"> <jats:title>Material and methods</jats:title> <jats:p>Apoptotic effect of Rituximab in the TANOUE (B-ALL) and EHEB (B-CLL) cell lines were evaluated by using the Annexin V method. mRNA expression levels of STAT3 and RelA were analysed by quantitative RT-PCR (Q-PCR). Alterations in STAT3 and RelA protein expressions were detected by using a chromogenic alkaline phosphatase assay after Western Blotting.</jats:p> </jats:sec> <jats:sec id="j_tjb-2018-0321_s_997_w2aab3b7c29b1b6b1aab1c15b3Aa"> <jats:title>Results</jats:title> <jats:p>Rituximab had no apoptotic effect on both cell lines. Complement-mediated cytotoxicity was only detected in EHEB cells. mRNA and protein expressions of STAT3 and RelA genes were decreased following Rituximab treatment.</jats:p> </jats:sec> <jats:sec id="j_tjb-2018-0321_s_996_w2aab3b7c29b1b6b1aab1c15b4Aa"> <jats:title>Conclusion</jats:title> <jats:p>Our preliminary results suggest that the use of Rituximab might be effective in B-ALL though both signaling pathways.</jats:p> </jats:sec> Effects of Rituximab on JAK-STAT and NF-κB signaling pathways in acute lymphoblastic leukemia and chronic lymphocytic leukemia Turkish Journal of Biochemistry |
| spellingShingle | Dalmızrak, Ayşegül, Günel, Nur Selvi, Tezcanlı Kaymaz, Burçin, Şahin, Fahri, Saydam, Güray, Kosova, Buket, Turkish Journal of Biochemistry, Effects of Rituximab on JAK-STAT and NF-κB signaling pathways in acute lymphoblastic leukemia and chronic lymphocytic leukemia, Biochemistry (medical), Clinical Biochemistry, Molecular Biology, Biochemistry |
| title | Effects of Rituximab on JAK-STAT and NF-κB signaling pathways in acute lymphoblastic leukemia and chronic lymphocytic leukemia |
| title_full | Effects of Rituximab on JAK-STAT and NF-κB signaling pathways in acute lymphoblastic leukemia and chronic lymphocytic leukemia |
| title_fullStr | Effects of Rituximab on JAK-STAT and NF-κB signaling pathways in acute lymphoblastic leukemia and chronic lymphocytic leukemia |
| title_full_unstemmed | Effects of Rituximab on JAK-STAT and NF-κB signaling pathways in acute lymphoblastic leukemia and chronic lymphocytic leukemia |
| title_short | Effects of Rituximab on JAK-STAT and NF-κB signaling pathways in acute lymphoblastic leukemia and chronic lymphocytic leukemia |
| title_sort | effects of rituximab on jak-stat and nf-κb signaling pathways in acute lymphoblastic leukemia and chronic lymphocytic leukemia |
| title_unstemmed | Effects of Rituximab on JAK-STAT and NF-κB signaling pathways in acute lymphoblastic leukemia and chronic lymphocytic leukemia |
| topic | Biochemistry (medical), Clinical Biochemistry, Molecular Biology, Biochemistry |
| url | http://dx.doi.org/10.1515/tjb-2018-0321 |